|Dr. Paul B. Bolno||Pres, CEO & Director||854.64k||2.13M||1974|
|Mr. Keith C. Regnante||Chief Financial Officer||501.86k||1.01M||1970|
|Dr. Christopher Francis Ph.D.||Sr. VP of Corp. Devel. & Head of Emerging Areas||493.13k||4.75M||1978|
|Dr. Chandra Vargeese||Sr. VP of Drug Discovery||573.77k||327.3k||1961|
|Dr. Michael A. Panzara||Chief Medical Officer||615.35k||530.81k||1967|
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd. to develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wave Life Sciences Ltd.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 4; Compensation: 7.